InterMune "buy"

12/27/06 - Deutsche Securities

NEW YORK, December 27 (newratings.com) - Analysts at Deutsche Bank Securities maintain their "buy" rating on InterMune Inc (ITMN). The target price is set to $32.

In a research note published yesterday, the analysts mention that the company can use the positive top line data for Shionogi’s PIII study of pirfenidone in idiopathic pulmonary fibrosis (IPF) to support its pirfenidone PIII "go" decision in IPF in 1Q07. InterMune’s pipeline includes two other viable products, namely Actimmune and ITMN-191, the analysts say. Rising visibility into ITMN-191 for HCV and an emerging pipeline are likely to support the company’s share price into next year, Deutsche Bank Securities adds.